Pfizer Total Liabilities 1986-2025 | PFE
Pfizer total liabilities from 1986 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Pfizer total liabilities for the quarter ending June 30, 2025 were $117.083B, a 8.68% decline year-over-year.
- Pfizer total liabilities for 2024 were $124.899B, a 8.97% decline from 2023.
- Pfizer total liabilities for 2023 were $137.213B, a 35.47% increase from 2022.
- Pfizer total liabilities for 2022 were $101.288B, a 2.62% decline from 2021.
Pfizer Annual Total Liabilities
(Millions of US $) |
| 2024 |
$124,899 |
| 2023 |
$137,213 |
| 2022 |
$101,288 |
| 2021 |
$104,013 |
| 2020 |
$90,756 |
| 2019 |
$104,148 |
| 2018 |
$95,664 |
| 2017 |
$100,141 |
| 2016 |
$111,776 |
| 2015 |
$102,384 |
| 2014 |
$95,944 |
| 2013 |
$95,481 |
| 2012 |
$104,120 |
| 2011 |
$105,381 |
| 2010 |
$106,749 |
| 2009 |
$122,503 |
| 2008 |
$53,408 |
| 2007 |
$50,258 |
| 2006 |
$44,188 |
| 2005 |
$51,206 |
| 2004 |
$54,800 |
| 2003 |
$51,398 |
| 2002 |
$26,406 |
| 2001 |
$20,860 |
| 2000 |
$17,434 |
| 1999 |
$11,687 |
| 1998 |
$9,492 |
| 1997 |
$7,403 |
| 1996 |
$7,713 |
| 1995 |
$7,223 |
| 1994 |
$6,775 |
| 1993 |
$5,465 |
| 1992 |
$4,872 |
| 1991 |
$4,574 |
| 1990 |
$3,960 |
| 1989 |
$3,789 |
| 1988 |
$357 |
| 1987 |
$3,018 |
| 1986 |
$1,790 |
| 1985 |
$1,503 |
Pfizer Quarterly Total Liabilities
(Millions of US $) |
| 2025-06-30 |
$117,083 |
| 2025-03-31 |
$117,391 |
| 2024-12-31 |
$124,899 |
| 2024-09-30 |
$126,918 |
| 2024-06-30 |
$128,218 |
| 2024-03-31 |
$128,537 |
| 2023-12-31 |
$137,213 |
| 2023-09-30 |
$117,817 |
| 2023-06-30 |
$120,875 |
| 2023-03-31 |
$94,381 |
| 2022-12-31 |
$101,288 |
| 2022-09-30 |
$102,459 |
| 2022-06-30 |
$107,821 |
| 2022-03-31 |
$101,155 |
| 2021-12-31 |
$104,013 |
| 2021-09-30 |
$103,221 |
| 2021-06-30 |
$99,605 |
| 2021-03-31 |
$89,953 |
| 2020-12-31 |
$90,756 |
| 2020-09-30 |
$113,487 |
| 2020-06-30 |
$113,370 |
| 2020-03-31 |
$100,998 |
| 2019-12-31 |
$104,148 |
| 2019-09-30 |
$105,051 |
| 2019-06-30 |
$96,274 |
| 2019-03-31 |
$96,263 |
| 2018-12-31 |
$95,664 |
| 2018-09-30 |
$96,174 |
| 2018-06-30 |
$94,856 |
| 2018-03-31 |
$94,071 |
| 2017-12-31 |
$100,141 |
| 2017-09-30 |
$111,041 |
| 2017-06-30 |
$109,863 |
| 2017-03-31 |
$110,038 |
| 2016-12-31 |
$111,776 |
| 2016-09-30 |
$114,829 |
| 2016-06-30 |
$107,592 |
| 2016-03-31 |
$99,582 |
| 2015-12-31 |
$102,384 |
| 2015-09-30 |
$103,743 |
| 2015-06-30 |
$93,698 |
| 2015-03-31 |
$93,053 |
| 2014-12-31 |
$95,944 |
| 2014-09-30 |
$93,057 |
| 2014-06-30 |
$95,656 |
| 2014-03-31 |
$93,740 |
| 2013-12-31 |
$95,481 |
| 2013-09-30 |
$97,167 |
| 2013-06-30 |
$100,358 |
| 2013-03-31 |
$104,571 |
| 2012-12-31 |
$104,120 |
| 2012-09-30 |
$100,488 |
| 2012-06-30 |
$102,881 |
| 2012-03-31 |
$102,006 |
| 2011-12-31 |
$105,381 |
| 2011-09-30 |
$105,602 |
| 2011-06-30 |
$106,936 |
| 2011-03-31 |
$104,423 |
| 2010-12-31 |
$106,749 |
| 2010-09-30 |
$103,347 |
| 2010-06-30 |
$104,193 |
| 2010-03-31 |
$105,031 |
| 2009-12-31 |
$122,503 |
| 2009-09-30 |
$75,044 |
| 2009-06-30 |
$76,104 |
| 2009-03-31 |
$62,491 |
| 2008-12-31 |
$53,408 |
| 2008-09-30 |
$47,914 |
| 2008-06-30 |
$49,946 |
| 2008-03-31 |
$51,133 |
| 2007-12-31 |
$50,258 |
| 2007-09-30 |
$42,420 |
| 2007-06-30 |
$42,309 |
| 2007-03-31 |
$37,995 |
| 2006-12-31 |
$44,188 |
| 2006-09-30 |
$38,873 |
| 2006-06-30 |
$43,061 |
| 2006-03-31 |
$43,350 |
| 2005-12-31 |
$51,206 |
| 2005-09-30 |
$43,536 |
| 2005-06-30 |
$46,999 |
| 2005-03-31 |
$55,403 |
| 2004-12-31 |
$54,800 |
| 2004-09-30 |
$53,846 |
| 2004-06-30 |
$53,256 |
| 2004-03-31 |
$53,241 |
| 2003-12-31 |
$51,398 |
| 2003-09-30 |
$51,527 |
| 2003-06-30 |
$53,976 |
| 2003-03-31 |
$28,085 |
| 2002-12-31 |
$26,406 |
| 2002-09-30 |
$25,923 |
| 2002-06-30 |
$23,738 |
| 2002-03-31 |
$21,642 |
| 2001-12-31 |
$20,860 |
| 2001-09-30 |
$19,910 |
| 2001-06-30 |
$19,125 |
| 2001-03-31 |
$17,398 |
| 2000-12-31 |
$17,434 |
| 2000-09-30 |
$17,316 |
| 2000-06-30 |
$17,071 |
| 2000-03-31 |
$10,037 |
| 1999-12-31 |
$11,687 |
| 1999-09-30 |
$11,453 |
| 1999-06-30 |
$10,989 |
| 1999-03-31 |
$9,980 |
| 1998-12-31 |
$9,492 |
| 1998-09-30 |
$9,532 |
| 1998-06-30 |
$8,203 |
| 1998-03-31 |
$7,766 |
| 1997-12-31 |
$7,403 |
| 1997-09-30 |
$7,942 |
| 1997-06-30 |
$8,558 |
| 1997-03-31 |
$7,901 |
| 1996-12-31 |
$7,713 |
| 1996-09-30 |
$8,050 |
| 1996-06-30 |
$7,635 |
| 1996-03-31 |
$7,286 |
| 1995-12-31 |
$7,223 |
| 1995-09-30 |
$7,540 |
| 1995-06-30 |
$8,116 |
| 1995-03-31 |
$7,819 |
| 1994-12-31 |
$6,775 |
| 1994-09-30 |
$6,248 |
| 1994-06-30 |
$6,315 |
| 1994-03-31 |
$5,766 |
| 1993-12-31 |
$5,465 |
| 1993-09-30 |
$6,020 |
| 1993-06-30 |
$5,776 |
| 1993-03-31 |
$5,237 |
| 1992-12-31 |
$4,872 |
| 1992-09-30 |
$4,626 |
| 1992-06-30 |
$4,488 |
| 1992-03-31 |
$4,370 |
| 1991-12-31 |
$4,574 |
| 1991-09-30 |
$3,906 |
| 1991-06-30 |
$3,966 |
| 1991-03-31 |
$3,606 |
| 1990-12-31 |
$3,960 |
| 1990-09-30 |
$3,487 |
| 1990-06-30 |
$3,394 |
| 1990-03-31 |
$3,189 |
| 1989-12-31 |
$3,789 |
| 1989-09-30 |
$3,176 |
| 1989-06-30 |
$3,320 |
| 1989-03-31 |
$3,093 |
| 1988-12-31 |
$357 |
| 1988-09-30 |
$3,025 |
| 1988-06-30 |
$3,057 |
| 1988-03-31 |
$2,905 |
| 1987-12-31 |
$3,018 |
| 1987-09-30 |
$2,027 |
| 1987-06-30 |
$2,053 |
| 1987-03-31 |
$1,787 |
| 1986-12-31 |
$1,790 |
| 1985-12-31 |
$1,503 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
